Japanese BAY86-9766 Monotherapy Phase I Study

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2010

Primary Completion Date

April 27, 2012

Study Completion Date

April 27, 2012

Conditions

Neoplasms

Interventions

DRUG

BAY86-9766

BAY86-9766 30 mg twice a day (bid).

DRUG

BAY86-9766

BAY86-9766 50 mg twice a day (bid).

DRUG

BAY86-9766

BAY86-9766 100 mg once a day (od)

DRUG

BAY86-9766

BAY86-9766 60 mg once a day (od)

Trial Locations (1)

Kashiwa